- Have any questions?
- 02 9247 6000
- media@commsroom.co
- Have any questions?
- 02 9247 6000
- media@commsroom.co
Menu
GenEmbryomics, a medical genetics company with world-leading intellectual property, announced the appointment of an additional independent director to its board. This strategic move is part of the company’s preparation for listing on a major US national exchange, underscoring its commitment to global expansion and enhancing corporate governance standards.
“We are thrilled to welcome Tess Burleson to our Board of Directors at this pivotal time,” said Paul Viney, Chairman of GenEmbryomics. “Her appointment is a testament to our commitment to strengthening our board with directors who bring a wealth of experience and expertise in healthcare, biotechnology, and strategic business development. We are confident that Tess’s contributions will be invaluable as we continue to advance our mission and prepare for our next phase of growth.”
Nick Murphy, PhD, Founder and CEO of GenEmbryomics, added, “The inclusion of Tess on our board is a significant milestone for GenEmbryomics. Tess’s extensive background in the commercialisation of medical research and her proven track record in strategic business ventures make her an exceptional asset to our team. Tess will play a critical role in guiding our strategic direction as we move towards a US national exchange listing.”
Tess Burleson, M.B.A., C.P.A., brings over two decades of experience in the healthcare, pharmaceutical, and biomedical R&D sectors. She has been instrumental in the commercialisation of intellectual property and has led numerous business ventures with successful exits into the public market. Her career started at KPMG, followed by significant roles in the healthcare industry, including President of a multi-state clinical research company, Chief Financial Officer of a health system, and in medical R&D organisations.
The appointment of Burleson is expected to further strengthen GenEmbryomics’ industry position, driving forward its strategic initiatives and enhancing its governance as the company continues on its journey towards a US national exchange listing.
This article was also published on Publlic Spectrum
Justin Lavadia is a content producer and editor at Public Spectrum with a diverse writing background spanning various niches and formats. With a wealth of experience, he brings clarity and concise communication to digital content. His expertise lies in crafting engaging content and delivering impactful narratives that resonate with readers.
